Novel EGFR Binding Proteins

Abstract

The present invention pertains to antigen-binding proteins binding to the ligand-binding site of EGFR and to clinically relevant EGFR escape mutations. Specifically, the present invention provides an antigen-binding protein comprising a first antibody variable domain and a second antibody variable domain, wherein the variable domains form a binding site that: specifically binds to a human epidermal growth factor (EGFR) variant having one or more of the mutations V441D, S464L, G465R, and S492R with a KD<10−5 molar determined by biolayer interferometry (BLI); and that does not bind to human EGFR having the mutation Q435P and/or double mutation F436A/I462A with a KD>10−5 molar determined by biolayer interferometry (BLI). The binding of the antigen-binding protein to human EGFR blocks ligand-induced activation of human EGFR.

Dependencies are inferred from the claim text.